The world-leading experts in MPN shared the top abstracts from ASH 2020 that they believe could have the greatest impact on clinical practice.
In this document, you will find comments from the MPN Hub Steering Committee members on the impact of mutation for MPN development and progression as well as exciting results from studies using novel drugs for the treatment of myelofibrosis and polycythemia vera. Furthermore, the latest data exploring the optimized use of interferon alpha will be featured.